Division of Cardiology, NewYork-Presbyterian Columbia University Irving Medical Center, New York, New York, USA.
Department of Cardiology, Cambridge University and Royal Papworth NHS Foundation Trusts, Cambridge, United Kingdom.
JACC Heart Fail. 2023 Sep;11(9):1165-1180. doi: 10.1016/j.jchf.2023.07.009.
Heart failure and cardiomyopathy are significant contributors to pregnancy-related deaths, as maternal morbidity and mortality have been increasing over time. In this setting, the role of the multidisciplinary cardio-obstetrics team is crucial to optimizing maternal, obstetrical and fetal outcomes. Although peripartum cardiomyopathy is the most common cardiomyopathy experienced by pregnant individuals, the hemodynamic changes of pregnancy may unmask a pre-existing cardiomyopathy leading to clinical decompensation. Additionally, there are unique management considerations for women with pre-existing cardiomyopathy as well as for those women with advanced heart failure who may be on left ventricular assist device support or have undergone heart transplantation. The purpose of this review is to discuss: 1) preconception counseling; 2) risk stratification and management strategies for pregnant women extending to the postpartum "fourth trimester" with pre-existing heart failure or "pre-heart failure;" 3) the safety of heart failure medications during pregnancy and lactation; and 4) management of pregnancy for women on left ventricular assist device support or after heart transplantation.
心力衰竭和心肌病是导致与妊娠相关死亡的重要原因,因为孕产妇发病率和死亡率一直在增加。在这种情况下,多学科心产科团队的作用对于优化母婴和胎儿结局至关重要。虽然围产期心肌病是孕妇最常见的心肌病,但妊娠期间的血液动力学变化可能会使先前存在的心肌病显现出来,导致临床失代偿。此外,对于患有先前存在的心肌病的妇女以及那些可能正在接受左心室辅助装置支持或已经接受心脏移植的患有晚期心力衰竭的妇女,有独特的管理注意事项。本综述的目的是讨论:1)孕前咨询;2)患有先前存在的心力衰竭或“预心力衰竭”的孕妇直至产后“第四个三月”的风险分层和管理策略;3)心力衰竭药物在妊娠和哺乳期的安全性;以及 4)左心室辅助装置支持或心脏移植后的妊娠管理。